Abstract
Introduction: The COVID-19 pandemic significantly impacted the treatment of breast cancer. Management deviated from standard practice. The Association of Breast Surgery (ABS) advised - aim for day case surgery with priority given to: estrogen receptor (ER)-ve, HER2+ve, and pre-menopausal ER+ve patients. Neoadjuvant chemotherapy was advised for inoperable disease only. Oncoplastic procedures and breast reconstruction was not advised. ER+ves were to be considered for bridging endocrine treatment. We audited this change in practice.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
